Diagonal Therapeutics Announces Publication of Data Characterizing the Healthcare System Cost and Impact of Hereditary Hemorrhagic Telangiectasia (HHT) in the American Journal of Hematology
"This study provides the first detailed analysis of the healthcare resource demands and costs associated with HHT, highlighting the substantial economic impact this disease places on patients and the health system," said Hanny Al-Samkari, M.D., the Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Massachusetts General Hospital, Associate Professor of Medicine at Harvard Medical School, and lead author of the study. "The findings underscore the urgent need for treatments that can effectively address the underlying cause of HHT and reduce the complications related to chronic bleeding and anemia, which are major cost drivers requiring hematologic support, hospital admissions, and emergency care."
HHT is the second most common inherited bleeding disorder globally, affecting approximately 1 in 4,000 to 5,000 people and an estimated 80,000 in the U.S. The disorder leads to recurrent severe epistaxis (nosebleeds), chronic gastrointestinal bleeding, heavy menstrual bleeding, and arteriovenous malformations (AVMs) in organs such as the lungs, liver, and brain. These AVMs can cause serious or fatal bleeding events and comorbidities, including chronic and recurrent iron deficiency anemia—which occurs in nearly 60% of HHT patients. Chronic anemia is well known to increase risk for hospitalizations, heart failure, and death. Currently, there are no FDA- or EMA-approved therapeutics for HHT worldwide, and treatments are largely limited to off-label use of costly immunomodulatory and antiangiogenic drugs.
The study leveraged Komodo Health's Healthcare Map® claims database* to analyze real-world healthcare costs for HHT patients in 2022 and 2023. Key findings from the publication include:
Per patient per year (PPPY) costs for people living with HHT are comparable to or surpass those of other rare and resource-intensive diseases.
Bleeding and its consequences were identified as the primary drivers of healthcare costs.
Mean PPPY costs for all HHT patients were >$19,000 across 2022 and 2023, about 20% higher than those for sickle cell disease.
For HHT patients with anemia, the mean PPPY costs were approximately $27,000, comparable to those associated with muscular dystrophy.
Patients with HHT receiving hematologic support (iron infusions and/or red blood cell transfusions) had mean PPPY costs of approximately $40,000, comparable to those associated with cystic fibrosis.
HHT patients with anemia, while accounting for nearly 60% of the HHT patient population, were responsible for approximately 80% of the direct medical costs.
Notably, the prevalence of liver transplantation among HHT patients, arising from complications of liver AVMs, was 40 times greater than in the general U.S. population.
'We are extremely grateful to partner with Dr. Al-Samkari and Cure HHT on this important study, as it puts into stark focus the impact of HHT and its associated complications on individuals and families living with this complex disease,' said Eric Duhaime, Senior Vice President of Corporate Development at Diagonal and co-author of the study. "We are committed to advancing a differentiated treatment that directly addresses the root cause of HHT and are encouraged by the compelling preclinical profile of our first-in-class, bispecific ALK1 agonist antibody. We look forward to advancing development of DIAG723 as a novel, potentially disease-modifying treatment option for people living with HHT."
*The Komodo Health's Healthcare Map® claims database includes de-identified data from over 330 million patients across commercial, Medicare, and Medicaid plans in the United States.
About Hereditary Hemorrhagic Telangiectasia (HHT) HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies. In HHT, loss of function point mutations in members of the TGF-ß receptor superfamily complex create abnormal blood vessels that are fragile and susceptible to rupture and bleeding. These bleeding events drastically reduce quality of life, result in emergency visits and hospitalizations, and lead to chronic anemia, necessitating frequent iron infusions or red blood cell transfusions in many patients. Solid organ arteriovenous malformations, if left untreated, are at risk of rupturing, resulting in lung and brain hemorrhage, stroke, heart failure, and death.
About Diagonal Therapeutics Diagonal Therapeutics is a biotechnology company advancing novel disease-modifying clustering antibodies that repair dysregulated signaling implicated in a range of illnesses. The Company's DIAGONAL Product Engine combines proprietary computational and experimental techniques to overcome historical challenges associated with antibody drug discovery and efficiently deliver optimized therapeutic assets. Diagonal's pipeline comprises clustering antibodies designed to selectively address the underlying cause of disease across hematology, hepatology, and nephrology, offering the potential to deliver life-changing therapies for patients. DIAG723, Diagonal's first-in-class clustering antibody, recently received orphan drug designation from the U.S. FDA and a positive opinion from the EMA for treating HHT. For more information, please visit www.diagonaltx.com.
Media ContactMarites CoulterMarites.coulter@deerfieldgroup.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Rectal Cancer Survival Not Tied to pCR
TOPLINE: According to a meta-analysis of randomized clinical trials (RCTs), pathologic complete response (pCR) was not associated with overall or disease-free survival in patients with rectal cancer, suggesting that the use of pCR as a surrogate endpoint for survival should be reexamined. METHODOLOGY: Neoadjuvant trials in rectal cancer are increasingly using pCR as a surrogate endpoint for long-term outcomes, following recommendations by the FDA in 2012. However, while some research has shown an association between pCR and improved survival in rectal cancer on the patient level, consensus on the trial-level validity of pCR as a surrogate is lacking. Researchers conducted a systematic review and meta-analysis of 25 RCTs involving 11,882 patients with rectal cancer who underwent neoadjuvant therapies (mostly chemo radiation) followed by surgical resection. The researchers assessed the correlation between pCR and both overall survival and disease-free survival. TAKEAWAY: Across trials that reported overall survival, weighted regression analysis revealed no correlation between pCR and overall survival (β, 0.37; 95% CI, -0.98 to 1.71; P = .57). Similarly, across trials reporting disease-free survival, there was no correlation between pCR and disease-free survival (β, -0.84; 95% CI, -2.55 to 0.87; P = .32). A sensitivity analysis conducted after excluding two studies with a high risk for bias also yielded null associations. The researchers performed subgroup analyses excluding studies that evaluated neoadjuvant radiation alone or included patients who did not receive curative resection and again found no association between pCR and either disease-free or overall survival. IN PRACTICE: 'Our trial-level analysis did not reveal a correlation between pCR and [disease-free survival] or [overall survival] in rectal cancer RCTs,' the authors of the study concluded. 'Our study's findings suggest a recommendation against using pCR as a [surrogate endpoint] for neoadjuvant therapies in rectal cancer until conclusive trial-level evidence of its association with long-term outcomes is firmly established.' SOURCE: This study, led by Kavin Sugumar, MD, Tulane University, New Orleans, and Jessica Jin Lie, MD, MPH, University of British Columbia, Vancouver, British Columbia, Canada, was published online in JAMA Network Open. LIMITATIONS: A subgroup analysis of total neoadjuvant therapy trials was not feasible due to insufficient sample size. Additionally, postsurgical therapies in patients without pCR may have improved outcomes, potentially diluting its association with survival. Mediation analysis was not possible due to lack of patient-level data. DISCLOSURES: The authors did not disclose any funding information. One author disclosed receiving personal fees from Novartis, consulting fees from Boehringer Ingelheim, and grants from Eli Lilly and Company and Taiho, outside the submitted work. Another author reported receiving royalties as a coauthor on several chapters of UpToDate. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
2 hours ago
- Medscape
FDA Calls for Better Opioid Safety Labeling
The FDA is requiring manufacturers of opioid pain medications to update safety labels to better emphasize risks linked to their long-term use, the agency announced in a new Drug Safety Communication. The changes are based on observations from a May meeting between the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, which met to discuss two postmarketing requirement studies that assessed risk for abuse, addiction, and overdose in long-term use of opioid analgesics. One of the observational studies showed that over 12 months of use, 1%-6% of the more than 2000 total participants met criteria for opioid addiction, 9% met criteria for prescription opioid abuse, and 22% met criteria for prescription opioid misuse. In the second study, 5-year cumulative incidence estimates for opioid overdose-related death ranged from 1.5%-4.0%. In addition, 17% of first opioid overdoses over the entire 5-11 year study period were fatal. The new safety-labeling requirements are a result of these findings, committee and public comments from the meeting, and recognition that there is currently an 'absence of adequate and well-controlled studies on long-term opioid effectiveness,' the FDA noted in a press release. 'The death of almost 1 million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,' FDA commissioner Marty Makary, MD, said in the release. 30-Day Warning The FDA has also called for a new prospective, randomized controlled trial to be conducted that will focus primarily on assessing risks and benefits of opioids used over the long term. For now, the updated labeling should include a better explanation of risks, stronger warnings about higher doses, clarification about use limits, an emphasis that long-acting or extended-release opioids should only be used if shorter-acting opioids or other medications have proven inadequate, and a reminder about serious harm that can come if a patient who becomes physically dependent does not stop opioid use. Additionally, the revised labels should provide information on possible opioid-related problems with the esophagus; on opioid overdose reversal agents; on toxic leukoencephalopathy, which can occur after overdose; and on negative drug-drug interactions, including gabapentinoids. 'This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and postmarket monitoring,' Makary said. The release noted that OxyContin's drug application was first approved without supportive long-term use data. The FDA added that manufacturers have 30 days to submit the newly required labeling updates for review.
Yahoo
3 hours ago
- Yahoo
Over 64,000 pounds of butter recalled over allergen concerns
A voluntary recall has been issued for over 64,000 pounds of butter found to contain an undeclared allergen. The voluntary recall was initiated July 14 by food ingredient company Bunge North America, affecting 1,800 cases of its NH European Style Butter Blend which did not declare milk as an allergen on the label. As of July 30, the Food and Drug Administration (FDA) labeled it a Class II recall, the second-highest risk level. A Class II recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. The butter was sent to 12 distribution centers located throughout the U.S., as well as a single distribution center located in the Dominican Republic. Affected cases were packaged in white paperboard and contained 36 blocks. Affected cases of butter contain the following identification information: Product code: 5023937 UPC: 1 00 78684 73961 2 Lot code: 5064036503 The butter recall is the latest in a string of food-and-drink-related issues across the U.S. Earlier this week, High Noon Hard Seltzers were recalled over a labeling error. Some cans, filled with High Noon Vodka Seltzer, were mislabeled as the non-alcoholic Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition. As a result, drinking the beverage in these cans can result in unintentional alcohol consumption. However, no illnesses or adverse events have been reported to date. Two lots of the High Noon Beach Variety 12-packs were affected, according to a press release. High Noon initiated the recall after it discovered 'a shared packaging supplier mistakenly shipped empty Celsius cans to High Noon,' according to the press release. The recalled High Noon Beach Variety 12-packs were sent to distributors in eight states who then shipped the product to retailers in six states — Florida, New York, Ohio, South Carolina, Virginia, and Wisconsin — between July 21 and 23. Even if they didn't purchase the High Noon packs, consumers are encouraged to ensure that their Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition, does not have the same lot codes as the recalled cans. Single-serve coffee pods have also been recalled this week. New Mexico Piñon Coffee announced in a press release that it was voluntarily recalling 154 boxes of its Dark Pinon Single Serve Cups, which have 10 pods per box. The recall was issued because of the 'potential introduction of food coloring into the cups,' which are compatible with Keurig machines, during brewing. The recalled coffee pods were sold at popular retailers nationwide, including Target, Costco, Walmart, and Kroger. Although there weren't any reports of illness or injury, consumers are urged to throw affected pods away or return them to the place of purchase.
